Rasio rega marang bathi Anbio Corp (NNNN)

Anbio Biotechnology generates revenue through the sale of analyzers and consumables, creating strong operating leverage. High certification and patent costs restrict new entrants from entering the sector. Stable government procurement ensures a steady cash flow, confirming the business's resilience. The company's P/E range clearly demonstrates the market valuation of earnings, where the current value is 24.90.

For an objective valuation of Anbio Biotechnology (NNNN), it is critical for a manager to understand the ratio of market capitalization to net income, which determines the investment payback period via operating cash flow. By analyzing the P/E ratio, an investor can identify the growth premium, which in this sector is justified by high barriers to entry due to the complexity of test certification and stringent patent protection.